Fig. 5: Neutralizing efficacy of Nb457 against live HIV-1 virus infection. | Nature Communications

Fig. 5: Neutralizing efficacy of Nb457 against live HIV-1 virus infection.

From: Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration

Fig. 5

a Illustration of the schematic structure of Nb457-NbHSA-Nb457, wherein the trimeric Nbs are interconnected by (G4S)3 linker. b–f Assessment of the neutralizing effects of Nb457-NbHSA-Nb457 (cyan line), Nb457-Fc (blue line) and Ibalizumab (green line) against five distinct live HIV-1 strains: HIV-1BAL (subtype B) (b), HIV-1CH058 (subtype B) (c), HIV-1THRO (subtype B) (d), HIV-1CH042 (subtype C) (e), and HIV-1CH198 (subtype C) (f). The negative control nanobody, Nb Ctl (gray dashed line), was employed. Data are presented as the mean ± standard error of the mean (SEM). g Compilation of IC50, IC80, IC90 and IC100 values alongside the corresponding data from the neutralization assay performed on live HIV-1 viruses, as detailed in panels b–f. Source data are provided as a Source Data file.

Back to article page